Brokers Issue Forecasts for AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Agios Pharmaceuticals in a report issued on Monday, February 24th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will post earnings of ($1.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.61) EPS, Q3 2025 earnings at ($1.40) EPS, FY2025 earnings at ($6.40) EPS, FY2026 earnings at ($7.35) EPS, FY2027 earnings at ($8.37) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($5.53) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Several other research analysts also recently weighed in on AGIO. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $56.57.

Agios Pharmaceuticals Trading Down 0.8 %

Shares of AGIO stock opened at $35.19 on Wednesday. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58. The business’s 50 day moving average is $34.01 and its two-hundred day moving average is $42.92. The company has a market capitalization of $2.02 billion, a P/E ratio of 3.10 and a beta of 0.88.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Venturi Wealth Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $33,000. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at about $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at about $53,000. Sterling Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 1,587 shares during the period. Finally, KBC Group NV increased its holdings in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the last quarter.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.